eHIV Review

eHIV Review


Latest Episodes

Newer NNRTI Agents in Clinical Practice
July 11, 2023

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine ap

Emerging HIV Therapies and Potential Clinical Uses
April 30, 2023

Hosted on Acast. See acast.com/privacy for more information.

Stigma and HIV Care in LGBTQ+ Persons
January 12, 2023

Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers nee

Newer Options for Treatment-Experienced Patients Podcast
October 11, 2022

Treatment-experienced patients with RAMs resistance-associated mutations remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patients ART history. How will new and in-devel

Weight Gain in PLWH: A Clinical Concern
September 07, 2022

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a return to health; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnor

COVID-19: The Morbidity/Mortality Risk
May 26, 2022

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)?Join Clinical Research

Clinical Uses of LA Injectable ART
April 07, 2022

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting A

Adolescents & Young Adults: Engaging the Vulnerable 20%
March 22, 2022

Twenty percent of new HIV diagnoses occur among adolescents and young adults. Theyre a population underserved by HIV prevention resources, with lower retention in HIV care. Their awareness and uptake of PrEP has been and remains low. What can their

Rapid ART: Benefits and Clinical Considerations
March 08, 2022

Rapid ART initiating ART as soon as possible after an HIV diagnosis: How effective is it at bringing people with newly diagnosed HIV into lasting care? When and how should it be initiated? Are there particular populations where attempting rapid ART shou

Engaging Undocumented Latinx People In HIV Care
March 08, 2022

Undocumented LatinX immigrants are a special population facing many difficulties that hinder their engagement in HIV care and prevention. One obvious barrier is language: many undocumented immigrants do not understand either spoken or